April 14th, 2:00 pm – 3:00 pm CEST


What is the current status of MAPPs in Europe and the US?

 Download the presentations here:

 gigi-slide  slide-james
 Gigi Hirsch  James Anderson


lucapani gigi-hirsch
Luca Pani,
Director General,
Italian Medicines Agency
Gigi Hirsch,
Executive Director,
CBI and Program Director,
James Anderson,
Head of Corporate Government Affairs,
GlaxoSmithKline, UK
Duane Schulthess,
Managing Director,
Vital Transformation


What is the current status of MAPPs in Europe and the US?

After nearly a decade of discussion, analysis and development, Medicine’s Adaptive Pathways to Patients (MAPPs) is beginning to see acceptance from regulators, industry, patients, and payers with the first live pilot project initiated under the guidance of the European Medicine’s Agency (EMA) in 2014. What is the status of MAPPs today, in Europe and the US – and how can we continue to drive progress on both sides of the Atlantic?

The topics of discussion:

  • The EMA adaptive licensing pilot scheme
  • The STAMP initiative of the European Commission
  • MIT NEWDIGS launch of their new data programme
  • Second Innovative Medicines Initiative IMI2 (CSA – Community Support Action)